1-(2-bromopyridin-4-yl)-1-methylethylamine | 1220127-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(2-bromopyridin-4-yl)-1-methylethylamine
• 英文别名: 2-(2-Bromopyridin-4-yl)propan-2-amine
• CAS: 1220127-22-9
• 化学式: C₈H₁₁BrN₂
• 分子量: 215.093
• InChiKey: YFBWZHJDKMUKOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-bromopyridin-4-yl)-1-methylethylamine 、 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 反应 16.0h， 以80 mg的产率得到(1-(4-(4-(2-aminopropan-2-yl)pyridin-2-yl)phenyl)-3-ethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)(morpholino)methanone
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS INDOLE ET INDAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTÉRASE

  摘要：

  该发明涉及新型吲哚和吲唑化合物，其特征在于该化合物具有通式（I），其中化学基团、取代基、变量和指数如描述中所定义，并且用作药物，特别是用作治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。

  公开号：

  WO2018234353A1

文献信息

• [EN] NOVEL SUBSTITUTED SPIRO-[INDOLINE HETEROCYCLOALKANE] COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS SPIRO-[INDOLINE HETEROCYCLOALKANE] SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE
  申请人：GRUENENTHAL GMBH

  公开号：WO2017108204A1

  公开（公告）日：2017-06-29

  The invention relates to novel spiro-[indoline heterocycloalkane] compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  这项发明涉及新型螺[吲哚杂环烷]化合物，其特征在于该化合物具有通式(I)，其中化学基团、取代基、变量和指数如描述中所定义，并且用作药物，特别是用作治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。
• [EN] NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 3-INDOLE ET 3-INDAZOLE SUBSTITUÉS UTILISÉES EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：GRUENENTHAL GMBH

  公开号：WO2018234354A1

  公开（公告）日：2018-12-27

  The invention relates to novel 3-indole and 3-indazole compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents. variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  本发明涉及一种新型的3-吲哚和3-吲唑化合物，其特征在于该化合物具有一般式（I），其中化学基团、取代基、变量和指数如描述中所定义，并且其用作药物，特别是用作通过抑制PDE4酶治疗可以治疗的疾病和病症的药物。
• Azaindazole Compounds As CCR1 Receptor Antagonists
  申请人：COOK Brian Nicholas

  公开号：US20100093724A1

  公开（公告）日：2010-04-15

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  本发明涉及式(I)化合物，其可用于治疗多种疾病和障碍，这些疾病和障碍是通过CCR1的活性介导或维持的，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。同时，本发明还涉及制备方法和使用方法。
• Heterocyclic Compounds As CCR1 Receptor Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20120270879A1

  公开（公告）日：2012-10-25

  Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

  本发明涉及式(I)的CCR1受体拮抗剂，其中Ar1、Ar2、R1-R3、X和L在此披露。本发明还涉及式(I)化合物的组合物、制备方法和使用方法。
• Pyridinyl Compounds Useful As Intermediates
  申请人：COOK Brian Nicholas

  公开号：US20120136158A1

  公开（公告）日：2012-05-31

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

  本发明涉及一种式(I)的化合物，可用于治疗多种通过CCR1活性介导或维持的疾病和障碍，包括自身免疫性疾病，例如类风湿性关节炎和多发性硬化症。本发明还涉及其中间体，以及制备和使用它们的方法。